[Treatment of epidermoid head and neck cancer with cisplatinum/bleomycin vs methotrexate/vindesine].
Treatment of patients with advanced squamous head and neck tumors demonstrates even with best surgical and x-ray techniques only five year survival rats between 10 and 30%. Chemotherapy in addition seems to improve these results. From July 79 to January 80 21 patients with advanced squamous-cell carcinoma at the head and neck region were treated in a controlled pilot study with Cisplatinum/Bleomycin or Methotrexate/vindesine. 6 patients were primarily treated with chemotherapy, all other secondary progressive disease after surgical and x-ray procedure. Without respect to the generally cell tolerated therapy modality on overall remission induction rate of 50 and 70% was observed. In a subsequent randomized controlled multicentric study both regimes will be compared concerning remission, survival and toxicity.
D001761:Bleomycin / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D011379:Prognosis; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014751:Vindesine
D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin; D014751:Vindesine; D008727:Methotrexate
Zytostatische Therapie von Plattenepithelkarzinomen im Kopf-Hals-Bereich mit Cisplatin/Bleomycin oder Methotrexat/Vindesin.